Dedicated locality research platform
Enter your email address and you will receive
a link to reset your password
Medi Assist Healthcare Services, a prominent player in India's healthcare landscape, has embarked on a transformative journey by submitting its draft red herring prospectus (DRHP) to SEBI, the capital markets regulator, signalling its intent to launch an initial public offering (IPO). Headquartered in Bengaluru, Medi Assist plays a pivotal role as a healthcare benefits administrator. The unveiled DRHP outlines a unique IPO structure, one that exclusively comprises an offer-for-sale (OFS) mechanism. In this arrangement, existing shareholders and company promoters will tender up to 2.80 crore equity shares, each with a face value of Rs 5. Notably, the company itself will not receive any proceeds from this offering.
Key stakeholders, including Vikram Jit Singh Chhatwal, Medimatter Health Management, Bessemer Health Capital LLC, Investcorp Private Equity Fund I, Vivek Pandit, Rahul M Khanna, Shankar Rao Palepu, Pramod Manohar Ahuja, Keshav Sanghi, Amitkumar Gajendrakumar Patni, and other associated entities, are set to actively participate in this OFS. Medi Assist Healthcare Services is intrinsically intertwined with India's insurance ecosystem, acting as a crucial intermediary bridging insurers and policyholders, insurance providers and healthcare institutions, and government bodies and beneficiaries of public health schemes.
Significantly, it holds the distinction of being India's largest healthcare benefits administrator, managing a substantial share of premium funds under both retail and group policies. The F&S Report highlights the company's dominance, showcasing an impressive market share of 14.83 percent in the retail health insurance sector and a commanding 41.71 percent in the group health insurance segment. As of the conclusion of the 2023 financial year, the company had overseen a staggering Rs 14,574.65 crore in health insurance premiums, encompassing both group and retail policies. This figure underscores substantial growth, with a remarkable compound annual growth rate (CAGR) of 35.67 percent from the Rs 7,918.49 crore recorded at the conclusion of the 2021 financial year.
As of March 31, 2023, the company had nurtured strategic partnerships with 36 insurance firms, spanning the Indian market and extending to the global arena. The IPO allocation strategy has been meticulously structured: 50 percent of the shares will be reserved for qualified institutional bidders (QIBs), with an additional 15 percent set aside for non-institutional investors (NIIs). The remaining 35 percent will be accessible to retail investors, promising a well-rounded participation opportunity. This momentous IPO endeavour is being expertly facilitated by a consortium of book-running lead managers, including Axis Capital, IIFL Securities, Nuvama Wealth Management, and SBI Capital Markets.
Simultaneously, the critical role of the registrar in the issue has been entrusted to Link Intime India. Following the IPO, the stock is poised for trading on both the BSE and NSE, marking an exciting new chapter in the journey of Medi Assist Healthcare Services as it steps into the realm of publicly traded companies. With a strategic allocation strategy catering to various investor categories, it promises an inclusive participation opportunity. As the IPO unfolds, it marks a significant milestone in the company's evolution, offering investors a chance to be part of its promising future in the healthcare landscape.
Propscience is India’s dedicated property news portal. We cover the latest events, news, trends, deals, new launches and more.
All our services and tools are completely free of cost and available 24X7!
We use cookies to give you the best possible service while using our website, please click accept and carry on browsing if you're happy with this. For more information see our Privacy Policy.
Okay, Got it!This disclaimer ("Disclaimer") is applicable to the entire Site. Upon entering the Site it is recommended that you immediately read the Terms and Conditions and Privacy Policy listed therein. Your continued usage of this Site will indicate your unconditional acceptance of the said Terms and Conditions and Privacy Policy. You hereby agree that Propscience reserves the right to modify at any time, the Terms and Conditions and Privacy Policy governing this Site without prior notification. Your usage of the Site implies that you will be bound by any such modification. You agree and acknowledge that it is your responsibility to periodically visit the Site and stay updated with the Terms and Conditions and Privacy Policy of the Website.
The information contained in this Site has been provided by Propscience for information purposes only. This information does not constitute legal, professional or commercial advice. Communication, content and material within the Site may include photographs and conceptual representations of projects under development. All computer-generated images shown on the Site are only indicative of actual designs and are sourced from third party sites.
The information on this Site may contain certain technical inaccuracies and typographical errors. Any errors or omissions brought to the attention of Propscience will be corrected as soon as possible. The content of this Site is being constantly modified to meet the terms, stipulations and recommendations of the Real Estate Regulation Act, 2016 ("RERA") and rules made thereunder and may vary from the content available as of date. All content may be updated from time to time and may at times be out of date. Propscience accepts no responsibility for keeping the information in this website up to date or any liability whatsoever for any failure to do so.
While every care has been taken to ensure that the content is useful, reliable and accurate, all content and information on the Site is provided on an "as is" and "as available" basis. Propscience does not accept any responsibility or liability with regard to the content, accuracy, legality and reliability of the information provided herein, or, for any loss or damage caused arising directly or indirectly in connection with reliance on the use of such information. No information given under this Site creates a warranty or expands the scope of any warranty that cannot be disclaimed under applicable law.
This Site provides links to other websites owned by third parties. Any reference or mention to third party websites, projects or services is for purely informational purposes only. This information does not constitute either an endorsement or a recommendation. Propscience accepts no responsibility for the content, reliability and information provided on these third-party websites. Propscience will not be held liable for any personal information of data collected by these third parties or for any virus or destructive properties that may be present on these third-party sites.
Your use of the Site is solely at your own risk. You agree and acknowledge that you are solely responsible for any action you take based upon this content and that Propscience is not liable for the same. All details regarding a project/property provided on this Site are updated on the basis of information available from the respective developers/owners/promoters. All such information will not be construed as an advertisement. To find out more about a project / development, please register/contact us to visit the site you are interested in. All decisions taken by you in this regard will be taken independently and Propscience will not be liable for any such loss in connection with the same. This Site is for guidance only. Your use of this Site - including any suggestions set out in the Site and or any use of the resources available on this Site, do not create any professional - client relationship between you and Propscience. Propscience cannot accept you as a client until certain formalities and requirements are met.
We use cookies to give you the best possible service while using our website, please accept it and continue browsing if you're happy with this. For more information see our Privacy Policy